Abstract

*Zukhra Hamidovna Alieva

ABSTRACT

Purpose: to study the relationship of hemodynamic parameters with the main markers of heart failure in patients with breast cancer and the incidence of side effects of chemotherapy according to the AC regimen in combination with doxorubicin. Material and Methods: 27 patients with breast cancer were examined after surgical treatment. All patients received both neoadjuvant and adjuvant chemotherapy (CT). The latter was carried out according to the AC scheme (doxorubicin 60-100 mg/m2 + cyclophosphamide 600 mg/m2 on the 1st day, every 21 days). All general clinical and laboratory studies were carried out. Results: women with breast cancer, as the number of courses of CT in combination with doxorubicin increased, despite a relatively young age, were characterized by a more pronounced tendency to tachycardia, the formation of arrhythmias and a decrease in exercise tolerance (ET), which, in turn, aggravated the phenomena of chronic HF in the form of a decrease in SV and LVEF. In addition, it was found that treatment with large doses of doxorubicin contributed to the formation of heart failure while maintaining central hemodynamic parameters. In 14.8% of cases, CT according to the AS regimen in combination with doxorubicin was accompanied by a high level of emetogenicity, which emphasizes the need for an integrated (oncological, cardiological, gastroenterological, etc.) approach in providing medical care to this group of patients. Conclusion: AC chemotherapy (doxorubicin + cyclophosphamide) remains the most commonly prescribed adjuvant regimen in the treatment of breast cancer. However, the toxicity of oncological drugs requires new approaches to solving this serious problem of modern health care. The range of application of doxorubicin in the treatment of malignant neoplasms is extensive, which allows it to be classified as a first-line drug, at the same time, its cardiotoxicity should alert specialists when prescribing it.